Table 2.
Prescription status of all participants at baseline
| Variable | Value |
|---|---|
| The composition of prior triple combination at baseline | |
| Metformin | 347 (97.1) |
| Sulfonylurea or glinide | 317 (88.8) |
| DPP4 inhibitor | 286 (80.1) |
| Thiazolidinedione | 77 (21.6) |
| SGLT2 inhibitor | 26 (7.3) |
| α-Glucosidase inhibitor | 18 (5.0) |
| OHAs newly added as quadruple combination | |
| Thiazolidinedione | 202 (55.2) |
| SGLT2 inhibitor | 83 (22.7) |
| DPP4 inhibitor | 47 (12.8) |
| Sulfonylurea or glinide | 21 (5.7) |
| α-Glucosidase inhibitor | 10 (3.3) |
| Metformin | 1 (0.3) |
| Antihypertensive agents at baseline | |
| ACE inhibitors | 23 (6.4) |
| Angiotensin receptor blocker | 166 (46.5) |
| Calcium channel blocker | 89 (24.9) |
| β-Blocker | 47 (13.2) |
| Nitrate | 3 (0.8) |
| Diuretics | 23 (6.4) |
| Lipid lowering agents at baseline | 280 (78.4) |
| Antiplatelet agents at baseline | 152 (42.6) |
Values are presented as number (%).
DPP4, dipeptidyl peptidase 4; SGLT2, sodium-glucose cotransporter 2; OHA, oral hypoglycemic agent; ACE, angiotensin-converting enzyme.